Non-malignant causes of hypercalcemia in cancer patients: A frequent and neglected occurrence

Supportive Care in Cancer

Volumn 21, Issue 5, 2013, Pages 1415-1419

  Soyfoo, M S ^a   Brenner, K ^b   Paesmans, M ^c   Body, J J ^d  

^a ERASME HOSPITAL   (Belgium)

^b WILHELMINEN HOSPITAL   (Austria)

^c JULES BORDET INSTITUTE   (Belgium)

^d BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bone metastases; Breast cancer; Hypercalcemia; Hyperparathyroidism; Lung cancer

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER REGRESSION; FEMALE; HUMAN; HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MILK ALKALI SYNDROME; PARANEOPLASTIC SYNDROME; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS;

ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; NEOPLASMS; PARATHYROID HORMONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84879694194     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1683-5     Document Type: Article

References (23)

1. Body JJ (2004) Hypercalcemia of malignancy. Semin Nephrol 24:48-54
2. Body JJ, Delmas PD (1992) Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475
3. Toori KU, Bone MF, Labib MH (1999) Raised urinary pyridinium cross-links in humoral hypercalcaemia of malignancy. Ann Clin Biochem 36(Pt 1):107-108
4. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ (1991) Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73:1309-1315
5. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M (2007) International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43:852-858
6. Santarpia L, Koch CA, Sarlis NJ (2010) Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res 42:153-164
7. Body JJ, Dumon JC, Thirion M, Cleeren A (1993) Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. J Bone Miner Res 8:701-706
8. Body JJ, Louviaux I, Dumon JC (2000) Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 8:398-404
9. Body JJ, Dumon JC (1994) Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann Oncol 5:359-363
10. Kim SJ, Shiba E, Maeda I, Yoshioka T, Amino N, Noguchi S (2001) Screening for primary hyperparathyroidism (PHPT) in clinic patients: differential diagnosis between PHPT and malignancy-associated hypercalcemia by routine blood tests. Clin Chim Acta 305:35-40
11. Motellon JL, Javort Jimenez F, de Miguel F, Jaras MJ, Diaz A, Hurtado J, Esbrit P (2000) Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy. Clin Chim Acta 290:189-197
12. Mundy GR, Cove DH, Fisken R (1980) Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1:1317-1320
13. Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) 41:407-413
14. Jacobs TP, Bilezikian JP (2005) Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab 90:6316-6322
15. Blomqvist CP (1986) Malignant hypercalcemia - a hospital survey. Acta Med Scand 220:455-463
16. Fisken RA, Heath DA, Bold AM (1980) Hypercalcaemia - a hospital survey. Q J Med 49:405-418
17. Ling PJ, A'Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 72:206-209
18. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304
19. Ralston SH, Fogelman I, Gardiner MD, Boyle IT (1984) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J 288:1405-1408
20. Rizzoli R, Thiebaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Ruckert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thurlimann B, Clemens MR, Eghbali H, Body JJ (1999) Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 84:3545-3550
21. Endres DB, Villanueva R, Sharp CF Jr, Singer FR (1991) Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 37:162-168
22. Body JJ, Dumon JC, Seraj F, Cleeren A (1992) Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:1385-1388
23. Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373-379